SEC For	rm 4																	
FORM 4 UNITED STAT				TES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See					AT OF CHANGES IN BENEFICIAL OWNER d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940												erage burde	3235-0287 n 0.5
1. Name and Address of Reporting Person [*] Schilsky <u>Richard</u>					2. Issuer Name and Ticker or Trading Symbol <u>LEAP THERAPEUTICS, INC.</u> [LPTX]								(Ch	Relationship o eck all applio X Directo	able)	g Pers	uer vner	
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 08/23/2023									Officer below)	(give title	ve title Other (sp below)		specify
C/O LEAP THERAPEUTICS, INC. 47 THORNDIKE STREET SUITE B1-1 (Street) CAMBRIDGE MA 02141				4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	Rule 10b5-1(c) Transaction Indication									l to								
1. Title of Security (Instr. 3) 2. Transa Date (Month/C				ction	ar) i	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3,		ed (A) or	5. Amou	nt of s ally ollowing	Form	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ction(s)			(
			Table II -						uired, D s, option					Owned				
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Example or Exercise (Month/Day/Year) if a		if any	ution Date, Tr		tion nstr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercise Expiration Date (Month/Day/Yea			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) Amount		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s Ily J	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				c	ode	v	(A)	(D)	Date Exercisabl		Expiration Date	Title	or Number of Shares					

Stock Option (Right to Buy) Explanation of Responses:

\$2.21

1. The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of November 23, 2023, February 23, 2024, May 23, 2024 and August 23, 2024 for so long as the reporting person continues to be a director, consultant or service provider of the Company.

(1)

/s/ Douglas E. Onsi as attorney-	00/05/0000	
in-fact for Richard Schilsky	08/25/2023	

\$<mark>0</mark>

15,000

D

** Signature of Reporting Person Date

15,000

08/23/2033

Common

Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

08/23/2023

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Α

15,000

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.